Apollomics released FY2024 Q1 earnings on August 14 (EST), actual revenue USD 785K (forecast USD 0), actual EPS USD -18.7673 (forecast USD -17)

Brief Summary

Apollomics reported Q1 2024 revenue of $785,000, which surpassed the $0 market expectation, while its EPS of -$18.7673 missed the projected -$17.

Impact of The News

Financial Performance Overview

Apollomics released its Q1 2024 financial results on August 15, 2024 (Beijing time), revealing a mixed performance relative to market expectations:

• Revenue Beat: The company reported actual revenue of $785,000, significantly exceeding the analyst expectation of $0.
• EPS Miss: The actual EPS was -$18.7673, which was lower than the anticipated -$17.
• Net Loss: The company recorded a total loss of $17,603,000 for the period.

Market Position and Peer Comparison

In the context of the broader market performance benchmarks observed in late 2025 and 2026:

• Scale of Operations: Compared to large-cap technology and consumer companies, Apollomics operates at a much smaller financial scale. For instance, while companies like Google and Meta report quarterly revenues in the tens of billions , Apollomics’ revenue remains in the sub-million dollar range, typical of early-stage biotechnology firms.
• Profitability Trends: Unlike established firms like Haidilao, which saw its first net profit decline in four years in 2025 , Apollomics is currently in a pre-profit phase characterized by significant net losses as it scales its operations.

Business Status and Transmission Paths

1. Insider Alignment: As of April 2026, the company’s Chief Operating Officer and Director, Yi-kuei (Alex) Chen, held a 5.3% beneficial ownership in Class A common stock TradingView. This substantial insider stake suggests a level of management commitment to the company’s long-term trajectory following the 2024 financial results.
2. Transmission to Valuation: Missing EPS expectations can trigger immediate negative market sentiment, a trend seen in other sectors where even slight misses or growth slowdowns (such as Microsoft’s Azure growth decelerating from 40% to 39%) can lead to significant share price corrections . For Apollomics, the deeper-than-expected loss may weigh on short-term valuation despite the revenue surprise.
3. Future Development: The transition from $0 expected revenue to $785,000 actual revenue indicates the commencement of commercial activities or milestone achievements. However, the high net loss underscores the continued high burn rate necessary for its business model.